DK2117571T3 - Urokinase-type plasminogenaktivatorreceptorepitop - Google Patents

Urokinase-type plasminogenaktivatorreceptorepitop Download PDF

Info

Publication number
DK2117571T3
DK2117571T3 DK07862653.8T DK07862653T DK2117571T3 DK 2117571 T3 DK2117571 T3 DK 2117571T3 DK 07862653 T DK07862653 T DK 07862653T DK 2117571 T3 DK2117571 T3 DK 2117571T3
Authority
DK
Denmark
Prior art keywords
upar
antibody
human
cells
binding
Prior art date
Application number
DK07862653.8T
Other languages
English (en)
Inventor
Graham Parry
Andrew P Mazar
Original Assignee
Monopar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc filed Critical Monopar Therapeutics Inc
Application granted granted Critical
Publication of DK2117571T3 publication Critical patent/DK2117571T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

1. Isoleret peptid af op til 40 aminosyrer omfattende aminosyresekvensen CCTKS-GCNHPDLDVQYRSG, CCTKSGCNHPDLDVQYRS, CCTKSGCNHPDLDVQYR, CCTKSGCNHPDLD-VQY eller CCTKSGCNHPDLDVQ, hvor den anden og tredje cysteinrest i sekvensen er disul-fidbundne til hinanden og danner en disulfidløkke.
2. Isoleret peptid ifølge krav 1 bestående af aminosyresekvensen CCTKSGCNHPDLD-VQYRSG, CCTKSGCNHPDLDVQYRS, CCTKSGCNHPDLDVQYR, CCTKSGCNHPDLDVQY eller CCTKSGCNHPDLDVQ.
3. Isoleret peptid ifølge krav 1 bestående af et fragment af humant uPAR som fremstillet i Figur 1.
4. Isoleret peptid ifølge krav 1 eller 3, hvor peptidet er op til 30 aminosyrer i længde.
5. Isoleret peptid ifølge krav 4, hvor peptidet er op til 20 aminosyrer i længde.
6. Isoleret peptid ifølge et hvilket som helst af kravene 1 og 3-5, hvor sekvensen af peptidet (i) består af et fragment af humant uPAR i hvilket Cys 265 er aminoterminus af peptidet; og (ii) omfatter aminosyresekvensen CCTKSGCNHPDLDVQYRS, CCTKSGCNHPDLDVQYR, CCTKSGCNHPDLDVQY eller CCTKSGCNHPDLDVQ.
7. Fremgangsmåde til fremstilling af et antistof, hvilken omfatter: (i) immunisering af et ikke-humant pattedyr med et immunogen omfattende et peptid ifølge et hvilket som helst af kravene 1 til 6; (ii) isolering af splenocytter fra pattedyret; (iii) splejsning af splenocytterne til myelomceller; og (iv) selektion af et hybridom, som secernerer et antistof, der binder peptidet.
DK07862653.8T 2006-12-08 2007-12-07 Urokinase-type plasminogenaktivatorreceptorepitop DK2117571T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US93003407P 2007-05-11 2007-05-11
PCT/US2007/025105 WO2008073312A2 (en) 2006-12-08 2007-12-07 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2117571T3 true DK2117571T3 (da) 2017-05-08

Family

ID=39512272

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07862653.8T DK2117571T3 (da) 2006-12-08 2007-12-07 Urokinase-type plasminogenaktivatorreceptorepitop

Country Status (9)

Country Link
US (1) US8105602B2 (da)
EP (1) EP2117571B1 (da)
JP (2) JP2010512324A (da)
CA (1) CA2671971C (da)
DK (1) DK2117571T3 (da)
ES (1) ES2636451T3 (da)
PL (1) PL2117571T3 (da)
PT (1) PT2117571T (da)
WO (1) WO2008073312A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101022830A (zh) * 2004-05-25 2007-08-22 阿特努奥恩公司 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途
DK2117571T3 (da) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogenaktivatorreceptorepitop
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
WO2011100620A2 (en) * 2010-02-12 2011-08-18 The Regents Of The University Of California Upar binding agents and methods of use thereof
JP2014502965A (ja) 2010-12-22 2014-02-06 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ ｕＰＡＲアンタゴニストおよびその使用
WO2013020898A1 (en) 2011-08-05 2013-02-14 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
WO2015017386A1 (en) * 2013-08-01 2015-02-05 The General Hospital Corporation NON-GLYCOSYLATED suPAR BIOMARKERS AND USES THEREOF
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
CA3182769A1 (en) * 2020-06-15 2021-12-23 Andrew P. Mazar Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
JP2024520180A (ja) * 2021-05-21 2024-05-21 ノーススター メディカル テクノロジーズ リミテッド ライアビリティ カンパニー ウロキナーゼプラスミノーゲンアクチベーター受容体標的放射性医薬品
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
CA3245469A1 (en) * 2022-03-07 2023-09-14 Rush University Medical Center NEW TREATMENT FOR DIABETES AND KIDNEY DISEASE BY INHIBITION OF THE D2D3 PROTEIN UPAR PROTEOLYTIC
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院（深圳福田） 一种识别uPAR的纳米抗体及其应用
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026019458A1 (en) 2024-07-19 2026-01-22 Monopar Therpeutics, Inc Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5891664A (en) 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5519120A (en) 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
JPH04506148A (ja) 1989-04-07 1992-10-29 カンサーフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング） ウロキナーゼ型プラスミノーゲン活性化因子レセプター
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
ES2179036T3 (es) 1990-10-18 2003-01-16 Cancerforskningsfonden Af 1989 .nticuerpos contra el receptor uroquinasa y su uso
US5561220A (en) 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
EP0642354A4 (en) 1991-11-18 1995-07-12 Univ Michigan METHOD FOR DETECTING AND INSULATING uPA-R AND INHIBITING THE BOND uPA WITH uPA-R.
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
WO1993024141A1 (en) 1992-05-28 1993-12-09 The University Of Toledo Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US5618513A (en) 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
AU753157B2 (en) 1997-11-03 2002-10-10 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
CA2366514C (en) 1999-04-13 2009-09-15 Manfred Schmitt Diagnostic and therapeutic use of antibodies against the urokinase receptor
US7737256B2 (en) 2001-01-25 2010-06-15 Fondazione Centro San Raffaele Del Monte Tabor Antibody against uPA/uPAR
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
ATE524739T1 (de) 2002-02-13 2011-09-15 American Diagnostica Inc Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
US20030219837A1 (en) 2002-03-18 2003-11-27 Cress Anne E. Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
KR20060130588A (ko) 2003-11-18 2006-12-19 아테뉴온, 엘엘씨 우로키나제의 아미노 말단 단편에 결합하는 항체 및/또는이의 접합체, 조성물 및 이의 용도
US7541159B2 (en) 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
CN101022830A (zh) 2004-05-25 2007-08-22 阿特努奥恩公司 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途
EP1851543A2 (en) * 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
DK2117571T3 (da) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogenaktivatorreceptorepitop

Also Published As

Publication number Publication date
EP2117571A4 (en) 2010-08-04
EP2117571A2 (en) 2009-11-18
WO2008073312A3 (en) 2008-10-30
US8105602B2 (en) 2012-01-31
JP6019457B2 (ja) 2016-11-02
JP2010512324A (ja) 2010-04-22
PL2117571T3 (pl) 2017-08-31
ES2636451T3 (es) 2017-10-05
EP2117571B1 (en) 2017-03-08
WO2008073312B1 (en) 2008-12-18
PT2117571T (pt) 2017-06-14
JP2014224134A (ja) 2014-12-04
CA2671971C (en) 2021-03-30
WO2008073312A2 (en) 2008-06-19
CA2671971A1 (en) 2008-06-19
US20080199476A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
DK2117571T3 (da) Urokinase-type plasminogenaktivatorreceptorepitop
CA2568428C (en) Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
JP7524065B2 (ja) 抗ｔｉｇｉｔ抗体及びその使用
US8541565B2 (en) Polynucleotide encoding anti-CD14 antibody fusion protein
KR100951432B1 (ko) 혈액 응고를 억제하기 위한 항체 및 이의 사용 방법
KR101960004B1 (ko) Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법
CN111788228A (zh) 抗密蛋白18.2抗体及其用途
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
JPH07501806A (ja) ヒトｐｄｇｆベータ・レセプタに対する阻害性免疫グロブリン・ポリペプチド
CA2714657C (en) Anti-adam-15 antibodies and utilization of the same
US20240239873A1 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
US10640550B2 (en) Monoclonal antibody neutralizing infectivity of all ebola viruses
CN118359718A (zh) 抗cd93抗体及其应用
HK40094577B (zh) 抗密蛋白18.2抗体及其用途
HK40094578B (zh) 抗密蛋白18.2抗体及其用途
HK40094577A (zh) 抗密蛋白18.2抗体及其用途
HK40094578A (zh) 抗密蛋白18.2抗体及其用途